论文部分内容阅读
由于化疗对许多急性淋巴细胞白血病(ALL)患者有良好的疗效,骨髓移植通常仅用于该病的高危患者(包括化疗失败者),本文主要论述ALL治疗的选择及其结果,并讨论HLA匹配的相关或无关骨髓移植和自体骨髓移植的选择。采用同仲异基因骨髓移植于高危ALL,存活最长者是那些接受相匹配同胞骨髓的病人,特别是预处理用环磷酰胺加全身照射(TBI)者。本移植方法的局限在于符合条件的供髓者较少,只有不到1/3的患者具有相匹配的同胞供髓者。
Since chemotherapy has a good effect on many patients with acute lymphoblastic leukemia (ALL), bone marrow transplantation is usually used only in high-risk patients (including chemotherapy failure patients). This article mainly discusses the choice and results of ALL treatment, and discusses HLA matching. The choice of related or unrelated bone marrow transplantation and autologous bone marrow transplantation. Using homologous allogeneic bone marrow transplantation in high-risk ALL, the longest surviving patients were those who received matching sibling bone marrow, especially those pretreated with cyclophosphamide plus total body irradiation (TBI). The limitation of this transplantation method is that there are fewer eligible donors, and less than one-third of patients have matched sibling donors.